Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis

Inaoka, Pleiades Tiharu; Shono, Masato; Kamada, Mishio; Espinoza, J. Luis

doi:10.1186/s12929-019-0537-6

Cited by 36 publications

(21 citation statements)

References 162 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcoidosis overlaps with other autoimmune diseases, including rheumatoid arthritis, autoimmune thyroid disease, Sjogren's syndrome, and ankylosing spondylitis [63]. The role of the microbiota in these autoimmune diseases has been evaluated in previous studies and been shown to lay a significant role in their pathogenesis [64]; thus, study of the microbiome of sarcoidosis patients and its correlation with other diseases could open new avenues for investigating the underlying causes of this disease [65,66].…”

Section: Autoimmunitymentioning

confidence: 99%

Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments

Jain

Yadav

Puranik

et al. 2020

JCM

127

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous disease with nonspecific clinical manifestations that commonly affects the pulmonary system and other organs including the eyes, skin, liver, spleen, and lymph nodes. Sarcoidosis usually presents with persistent dry cough, eye and skin manifestations, weight loss, fatigue, night sweats, and erythema nodosum. Sarcoidosis is not influenced by sex or age, although it is more common in adults (< 50 years) of African-American or Scandinavians decent. Diagnosis can be difficult because of nonspecific symptoms and can only be verified following histopathological examination. Various factors, including infection, genetic predisposition, and environmental factors, are involved in the pathology of sarcoidosis. Exposures to insecticides, herbicides, bioaerosols, and agricultural employment are also associated with an increased risk for sarcoidosis. Due to its unknown etiology, early diagnosis and detection are difficult; however, the advent of advanced technologies, such as endobronchial ultrasound-guided biopsy, high-resolution computed tomography, magnetic resonance imaging, and 18F-fluorodeoxyglucose positron emission tomography has improved our ability to reliably diagnose this condition and accurately forecast its prognosis. This review discusses the causes and clinical features of sarcoidosis, and the improvements made in its prognosis, therapeutic management, and the recent discovery of potential biomarkers associated with the diagnostic assay used for sarcoidosis confirmation.

show abstract

Section: Autoimmunitymentioning

confidence: 99%

Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments

Jain

Yadav

Puranik

et al. 2020

JCM

127

View full text Add to dashboard Cite

show abstract

“…These involved comprehensive analysis of the bimolecular functional networks including the gene, protein, metabolite molecular signatures engraved at the host-microbe and microbe-microbe interface. This 'interspecies communication' have been linked now with immuno-pathogenesis of most human autoimmune disorders 82,83 . www.nature.com/scientificreports/ The etiopathology of these interactions have remained elusive leading to non-specific diagnostic criteria and therapeutic regimes.…”

Section: Discussionmentioning

confidence: 99%

Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach

Verma

Sharda

Rathi

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Reactive Arthritis (ReA), a rare seronegative inflammatory arthritis, lacks exquisite classification under rheumatic autoimmunity. ReA is solely established using differential clinical diagnosis of the patient cohorts, where pathogenic triggers linked to enteric and urogenital microorganisms e.g. Salmonella, Shigella, Yersinia, Campylobacter, Chlamydia have been reported. Inflammatory Bowel Disease (IBD), an idiopathic enteric disorder co-evolved and attuned to present gut microbiome dysbiosis, can be correlated to the genesis of enteropathic arthropathies like ReA. Gut microbes symbolically modulate immune system homeostasis and are elementary for varied disease patterns in autoimmune disorders. The gut-microbiota axis structured on the core host-microbe interactions execute an imperative role in discerning the etiopathogenesis of ReA and IBD. This study predicts the molecular signatures for ReA with co-evolved IBD through the enveloped host-microbe interactions and microbe-microbe ‘interspecies communication’, using synonymous gene expression data for selective microbes. We have utilized a combinatorial approach that have concomitant in-silico work-pipeline and experimental validation to corroborate the findings. In-silico analysis involving text mining, metabolic network reconstruction, simulation, filtering, host-microbe interaction, docking and molecular mimicry studies results in robust drug target/s and biomarker/s for co-evolved IBD and ReA. Cross validation of the target/s or biomarker/s was done by targeted gene expression analysis following a non-probabilistic convenience sampling. Studies were performed to substantiate the host-microbe disease network consisting of protein-marker-symptom/disease-pathway-drug associations resulting in possible identification of vital drug targets, biomarkers, pathways and inhibitors for IBD and ReA. Our study identified Na(+)/H(+) anti-porter (NHAA) and Kynureninase (KYNU) to be robust early and essential host-microbe interacting targets for IBD co-evolved ReA. Other vital host-microbe interacting genes, proteins, pathways and drugs include Adenosine Deaminase (ADA), Superoxide Dismutase 2 (SOD2), Catalase (CAT), Angiotensin I Converting Enzyme (ACE), carbon metabolism (folate biosynthesis) and methotrexate. These can serve as potential prognostic/theranostic biomarkers and signatures that can be extrapolated to stratify ReA and related autoimmunity patient cohorts for further pilot studies.

show abstract

“…Dysbiosis in the lung or gut may contribute to the development of systemic inflammatory conditions, including sarcoidosis. [11] The lung microbiota has been shown to contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. [12] In sarcoidosis patients, metabolomic profiling has shown changes in energy production, homocysteine, and amino acid metabolism, as well as a potential role of altered gut microbiota.…”

Section: Discussionmentioning

confidence: 99%

“…[5] Although the etiology of sarcoidosis progression is still largely unknown, recent studies propose a role for sex hormones [6][7][8][9] and the microbiome in the pathogenesis of fibrotic lung disease. [10][11][12] These gaps in knowledge limit the identification of effective treatments. Here, we present a patient with a fourteen-year history of symptomatic pulmonary sarcoidosis who experienced significant clinical improvement in lung function and chest radiographs following sleeve gastrectomy.…”

Section: Introductionmentioning

confidence: 99%

Improvement of pulmonary sarcoidosis following sleeve gastrectomy

Hassell¹,

Grzeszczak²,

Adams³

et al. 2019

CRIM

View full text Add to dashboard Cite

Pulmonary sarcoidosis is unlikely to resolve if it persists for greater than five years. A growing body of literature supports the involvement of the microbiome in sarcoidosis and a role for sex hormones in pulmonary fibrosis. Additionally, obesity is a risk factor for the development of sarcoidosis. Bariatric surgery is an effective treatment for obesity and can lead to microbial and endocrine changes. Here, we report the clinical improvement of longstanding pulmonary sarcoidosis following sleeve gastrectomy.

show abstract

Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis

Cited by 36 publications

References 162 publications

Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments

Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments

Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach

Improvement of pulmonary sarcoidosis following sleeve gastrectomy

Contact Info

Product

Resources

About